You are here

spinal muscular atrophy

New Zolgensma 'inflection point' is here as Novartis snags EU nod for SMA gene therapy

New Zolgensma 'inflection point' is here as Novartis snags EU nod for SMA gene therapy

Fierce Pharma

spinal muscular atrophy

Flag link:

Roche shares SMA data ahead of scrap with Biogen, Novartis

Roche shares SMA data ahead of scrap with Biogen, Novartis

Fierce Biotech

spinal muscular atrophy

clinical trials

Flag link:

With supply tight, Novartis readies gene therapy plant for production

With supply tight, Novartis readies gene therapy plant for production

BioPharma Dive

spinal muscular atrophy

drug manufacturing

Flag link:

Novartis' latest Zolgensma data bode well for use in older patients

Novartis' latest Zolgensma data bode well for use in older patients

Fierce Pharma

spinal muscular atrophy

Flag link:

Novartis, shadowed by data scandal, renews case for Zolgensma

Novartis, shadowed by data scandal, renews case for Zolgensma

Biopharma Dive

spinal muscular atrophy

Flag link:

Biogen ramps up its SMA rivalry with Novartis with new Spinraza trial

Biogen ramps up its SMA rivalry with Novartis with new Spinraza trial

Fierce Pharma

clinical trials

spinal muscular atrophy

Flag link:

Novartis used manipulated data in winning Zolgensma approval, FDA says

Novartis used manipulated data in winning Zolgensma approval, FDA says

Biopharma Dive

spinal muscular atrophy

Flag link:

Roche, PTC post latest SMA data from their attempt to rival Spinraza, Zolgensma

Roche, PTC post latest SMA data from their attempt to rival Spinraza, Zolgensma

Fierce Biotech

PTC Therapeutics

spinal muscular atrophy

Flag link:

New Zolgensma data suggest comparable efficacy to Spinraza — analysts

New Zolgensma data suggest comparable efficacy to Spinraza — analysts

Endpoints

spinal muscular atrophy

Flag link:

Novartis makes final Zolgensma pitch before FDA decision

Novartis makes final Zolgensma pitch before FDA decision

BioPharma Dive

spinal muscular atrophy

Flag link:

SMA Moment: Will Gene Therapy Shift Treatment, Costs of Muscle Disease?

SMA Moment: Will Gene Therapy Shift Treatment, Costs of Muscle Disease?

Xconomy

spinal muscular atrophy

Flag link:

Novartis mulling $1.5 mln-$5 mln price range for SMA gene therapy

Novartis mulling $1.5 mln-$5 mln price range for SMA gene therapy

Yahoo/Reuters

spinal muscular atrophy

Flag link:

Ionis slides after AveXis reports SMA data for Zolgensma

Ionis slides after AveXis reports SMA data for Zolgensma

BioCentury

Ionis Pharmaceuticals

lcinical trials

spinal muscular atrophy

Flag link:

With FDA decision near, Novartis bolsters SMA gene therapy case

With FDA decision near, Novartis bolsters SMA gene therapy case

Biopharma Dive

spinal muscular atrophy

Flag link:

Novartis' SMA gene therapy would not be cost-effective if priced over $1.5M: ICER

Novartis' SMA gene therapy would not be cost-effective if priced over $1.5M: ICER

Fierce Pharma

spinal muscular atrophy

Flag link:

ICER's life year calculation gives Novartis wider pricing ballpark for SMA therapy

ICER's life year calculation gives Novartis wider pricing ballpark for SMA therapy

BioCentury

spinal muscular atrophy

Flag link:

Novartis: Alternative payments will ‘reset the paradigm’ for covering gene, cell therapies

Novartis: Alternative payments will ‘reset the paradigm’ for covering gene, cell therapies

Fierce Pharma

spinal muscular atrophy

alternative payments

Flag link:

ICER says gene therapy may be more cost effective for spinal muscular atrophy

ICER says gene therapy may be more cost effective for spinal muscular atrophy

Yahoo/Reuters

spinal muscular atrophy

Flag link:

US benefits manager baulks after Novartis values gene therapy at $4-5 mln

US benefits manager baulks after Novartis values gene therapy at $4-5 mln

Yahoo/Reuters

Express Scripts

spinal muscular atrophy

Flag link:

Sticker shock: Novartis says its top drug prospect is worth $4M-$5M for a once-and-done use

Sticker shock: Novartis says its top drug prospect is worth $4M-$5M for a once-and-done use

Endpoints

spinal muscular atrophy

Flag link:

Pages